To bring COVID-19 vaccine to emerging and developing nations
COVAXX, a US company developing a multitope synthetic peptide-based vaccine to fight COVID-19, has announced a global logistics partnership with Maersk, one of the world’s largest shipping and integrated logistics providers.
The agreement lays out a framework for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 around the world, once approved by regulatory authorities. Financial terms of the agreement are not disclosed.
The mission of COVAXX is to defeat COVID-19 and ultimately democratize health worldwide. Maersk will help fulfill this mission by overseeing all logistics activities to ensure efficient transportation to developing countries.
The agreement provides for end-to-end supply chain management, packing and shipping, via air or ocean, ground transportation, warehouse storage and distribution to facilities to support COVAXX’s requirements for a pharmaceutical grade, temperature-controlled supply chain.
COVAXX is planning to manufacture 100 million doses of UB-612 during early 2021, and a billion doses by the end of 2021.
The design of the vaccine components will allow for the use of existing cold-chain storage and distribution channels, as the COVAXX vaccine does not require additional infrastructure such as -80⁰C freezers or liquid nitrogen tanks to store materials at extreme temperatures.
Lou Reese Co-Chief Executive Officer, COVAXX
“Our team, which now proudly includes Maersk, is committed to addressing the needs of countries where the greatest unmet needs exist today,” said Mei Mei Hu, co-Chief Executive Officer of COVAXX.
Rob Townley, Head of Special Project Logistics at Maersk said: “Efficient and safe delivery of COVID-19 vaccines around the world is the most urgent logistics challenge we face today.
"A. P. Moller – Maersk is committed to working closely with COVAXX to ensure smooth end-to-end global delivery of this vaccine as soon as it becomes available.”